Blood-based biomarkers reshape Alzheimer's disease diagnostic approach
Medical experts are sequencing plasma p-tau217 and beta-amyloid 42/40 testing alongside cognitive screening as first-line diagnostic tools for Alzheimer's disease, reserving confirmatory amyloid PET or CSF testing for inconclusive cases. Payer coverage for these biomarker tests has expanded, marking a shift in the diagnostic toolkit.